Evidence map›Paper›PMID 41602005›Full record

ArticleFrontiers in public health2025

Correction: Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia.

Ahmed Al-Jedai, Hajer Almudaiheem, Faisal A Al-Suweidan, Mohammed Al Jumah, Ahmed Al-Thobaiti, Fahad Alzureiqan, Wejdan Abu Ras, Fahad M Al-Dosari, Yaser Al Malik, Pratik Dhopte and 1 more

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ahmed Al-JedaiColleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.
Hajer AlmudaiheemThe Saudi Society of Clinical Pharmacy, Riyadh, Saudi Arabia.
Faisal A Al-SuweidanDivision of Neurology, Department of Medicine, Security Forces Hospital, Riyadh, Saudi Arabia.
Mohammed Al JumahKing Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Ahmed Al-ThobaitiKing Saud Medical City, Riyadh, Saudi Arabia.
Fahad AlzureiqanDrug Policy & Regulation Unit, Ministry of Health, Riyadh, Saudi Arabia.
Wejdan Abu RasTherapeutic Affairs Deputyship, Saudi Ministry of Health, Riyadh, Saudi Arabia.
Fahad M Al-DosariDepartment of Clinical Pharmacy, King Saud Medical City, Riyadh First Health Cluster (R1), Ministry of Health, Riyadh, Saudi Arabia.
Yaser Al MalikKing Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Pratik DhopteCarexso, Dubai, United Arab Emirates.
Rita OjeilPDC-CRO, Dubai, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fpubh.2025.1713092.].

Indexed as

budget impact analysisdisease-modifying therapiesmanaged entry agreementsmultiple sclerosisrelapsing-remitting multiple sclerosis

Identifiers

PMID41602005
PMCPMC12833429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.